VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Klompas, Zymeworks’ Chief Operating Officer and Chief F
SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that Ken Song, M.D., President and CEO of the Company, will be presenting at the 40
- January 10-13, 2022 (Virtual Conference) - MISSISSAUGA, Ontario--(BUSINESS WIRE)--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversifie
Amara’s organic plant-based baby food is now available in Loblaws locations nationwide across Canada, tapping demand for consumers seeking delicious, convenient, plant-based foods for their growing families. VANCOUVER, British Columbia--(BUSINESS WIRE)
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of innovative single access robotic-assisted surgery systems and technology, announced today it is schedul
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers today anno
The companies will identify and advance proprietary lead drug candidates uniquely suited to prevent metastatic recurrence. NATICK, Mass. & HOBOKEN, N.J. & MONTREAL--(BUSINESS WIRE)--Cyclenium Pharma, Inc. (“Cyclenium”), an emerging pharmaceutical com
Former CCO of Y-mAbs Therapeutics brings 20 years of pharma and biotech commercial leadership CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision
MONCTON, New Brunswick--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report ea
Co-founder Dr. Ali Tehrani to remain as an advisor to the Company to assist in the transition expected to occur on or before February 1, 2022 Chief Financial Officer (CFO) Neil Klompas also promoted to the dual position of Chief Operating Officer (COO
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.